Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07627620
PHASE2

Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer

Sponsor: Hunan Cancer Hospital

View on ClinicalTrials.gov

Summary

This study is an open-label, multi-center Phase II clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate and platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer.

Official title: A Multi-Center Phase II Clinical Study of Camrelizumab Combined With Famitinib Malate and Platinum-based Chemotherapy in the Treatment of Recurrent/Metastatic Cervical Cancer

Key Details

Gender

FEMALE

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

54

Start Date

2026-06-30

Completion Date

2029-03-30

Last Updated

2026-06-04

Healthy Volunteers

No

Conditions

Interventions

DRUG

Camrelizumab

Intravenous (IV) on Day 1 of each cycle

DRUG

Famitinib Malate

Famitinib po qd

DRUG

Chemotherapy

Paclitaxel + cisplatin or carboplatin